arGEN-X

Argenx, founded in 2008, is a pioneering biopharmaceutical company committed to developing cutting-edge therapeutics in the field of immunology. Headquartered in Breda, Netherlands, argenx leverages its proprietary antibody engineering technologies to create transformative medicines aimed at treating severe autoimmune diseases and cancer. The company focuses on understanding disease biology and translating these insights into clinical programs that address unmet medical needs.

With a robust pipeline of innovative solutions, argenx is at the forefront of drug development, dedicated to improving patient outcomes through advanced research and development. The company's approach involves a collaborative model, engaging with academic institutions, industry partners, and patient communities to accelerate the discovery and delivery of novel treatments. Argenx’s commitment to excellence is reflected in its strategic partnerships and its track record of bringing therapies from concept to clinical trials.

Under the leadership of CEO Tim Van Hauwermeiren, argenx continues to expand its global footprint and influence within the pharmaceutical industry. The company’s dedication to harnessing the power of immunology and its unwavering focus on innovation underscore its mission to provide life-changing therapies. Argenx stands as a testament to the transformative potential of biopharmaceutical advancements in addressing complex health challenges.